LOKELMA (AstraZeneca Pty Ltd)
Product name
LOKELMA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
206 (255 working days)
Active ingredients
sodium zirconium cyclosilicate hydrate
Registration type
NCE/NBE
Indication
LOKELMA is indicated for the treatment of hyperkalaemia in adult patients.